Global Breast Cancer Drugs Market Poised for US$ 52.35 billion by 2030 | mDataPartners

The global Breast Cancer Drugs market size was valued at US$ 19.73 billion in 2018 and US$ 34.8 billion in 2024. Global revenues are projected to be US$ 37.43 billion in 2025 and US$ 52.35 billion in 2030 growing at a CAGR of 7.05% from 2024 to 2030.

Driven by its high global prevalence, breast cancer - the world's most studied disease - commands a major share of oncology research, which itself is a cornerstone of the clinical development industry.

Breast Cancer Drugs Market - Global Outlook (2018-2030) published by mDataPartners provides a strategic, data-driven view of the global breast cancer therapeutics landscape, with detailed coverage of late-stage pipelines, regulatory milestones, competitive movements, and market forecasts through 2030 across all major therapeutic classes. Data has been updated to reflect the first nine months of 2025.

Download the free sample: https://mdatapartners.com/request-sample/pharmaceuticals/global-breast-cancer-drugs-market

Key Market Trends & Insights from the Breast Cancer Drugs Market Report
• Based on therapy, the targeted therapy segment captured the largest share of 86% in 2024. Targeted therapy drugs used to treat breast cancer include Monoclonal antibodies, Antibody-drug conjugates, Kinase inhibitors, CDK4/6 inhibitors, mTOR inhibitor, PI3K inhibitors, AKT inhibitor and PARP inhibitors.

• Antibody-drug conjugates: ADCs are revolutionizing the treatment of breast cancer. They are poised to become a standard of care across various stages of breast cancer. This class holds the strongest near-term potential with revenues projected to exceed USD 10 billion by 2030. HER2-targeted ADCs currently in Phase III trials (including candidates such as trastuzumab pamirtecan, ARX788, sacituzumab tirumotecan (sac-TMT), Trastuzumab botidotin, Patritumab deruxtecan, and JSKN003, to name a few) are being developed to demonstrate superiority or non-inferiority against the current standard.

• HER2-targeted therapy led the market with the largest revenue share of 39.6% in 2024 followed by CDK4/6 inhibitors (36.5% share in 2024). Lilly's Verzenio® (abemaciclib), CDK4/6 inhibitor has firmly established a leading position, holding 15% market share ($5.31 billion) in 2024 driven by strong clinical efficacy, expanding indications, and rapid adoption in both high-risk early and metastatic settings in HR+/HER2- breast cancer. HR+/HER2- breast cancer accounted to have the largest market size in 2024.

• AstraZeneca and Daiichi Sankyo's Enhertu- T-DXd is positioned to become the biggest breast cancer drug ever in 2030 (approximately $11.5 billion from all indications); its rapid uptake in approved patient populations (Eligible Patient Opportunity for ENHERTU® will Grow to > 80k in 2026 (HER2+ mBC; HER2+ eBC; HER2 low BC).

• Roche's Itovebi is set to become a cornerstone therapy in PIK3CA-mutated, HR-positive, HER2-negative breast cancer, propelled by the INAVO-120 trial's landmark 33% overall survival benefit - a first in the PI3K inhibitor class. With a safer profile and first line approval, Itovebi has clear clinical differentiation over Piqray, which remains confined to second-line use and lacks OS benefit.

• Triple-Negative Breast Cancer smallest but fastest growing segment accounted for approximately 8% of total breast cancer spending in 2024. Forecast to expand dramatically to $5 billion by 2030, maintaining a CAGR of ~12.5% from 2024 to 2030. Growth driven by immunotherapies like bispecific antibodies, PARP inhibitors, and ADC innovation (e.g. Datroway, Trodelvy). Datroway is projected to be the second-largest ADC launch of 2025, with global sales forecast at ~$6 billion by 2030.

• Next-generation hormonal therapies like Oral SERDs, PROTACs are poised to drive the next wave of breast cancer innovation by 2030, with market potential expected to exceed USD 6 billion beyond 2030. Key candidates include recently FDA-approved Lilly's Inluriyo (imlunestrant) as well as several Phase III candidates: Vepdegestrant (ARV-471) by Arvinas and Pfizer Inc., Camizestrant by AstraZeneca, Giredestrant by Genentech (Roche) & Gedatolisib by Celcuity Inc.

• Genetech (Roche) led the market in 2024 with a 28% market share, driven by its strong breast cancer portfolio -Perjeta, Kadcyla, Phesgo, and Herceptin-which collectively accounted for roughly 70% of HER2-therapy revenues in 2024.

Scope of the report includes below the therapies:

Targeted Therapy
• HER2-positive breast cancer:
o Monoclonal antibodies
o Antibody-drug conjugates
o Kinase inhibitors

• Hormone receptor-positive (HR+) breast cancer:
o CDK4/6 inhibitors
o mTOR inhibitors
o PI3K inhibitors
o AKT inhibitors

• BRCA-mutated breast cancer:
o PARP inhibitors

• Triple-negative breast cancer (TNBC):
o Antibody-drug conjugates

Immunotherapy (Immune Checkpoint Inhibitors)
• PD-1 inhibitors

Endocrine (Hormone) Therapy
• Selective Estrogen Receptor Modulators (SERMs)
• Selective Estrogen Receptor Degraders (SERDs)
• Aromatase Inhibitors (AIs)

Chemotherapy

Pipeline Insights:

Some of the drugs in the pipeline include
• Trastuzumab pamirtecan (BNT323/DB-1303) by BioNTech SE and Duality Biologics (Suzhou) Co., Ltd.
• Sacituzumab Tirumotecan (sac-TMT) by Kelun-Biotech/Merck
• Giredestrant by ROCHE
• RLY-2608 by Relay Therapeutics
• Camizestrant by AstraZeneca
• Saruparib (AZD5305) by AstraZeneca
• palazestrant (OP-1250) by Olema Oncology
• Gedatolisib by Celcuity Inc.
• vepdegestrant (ARV-471) by Pfizer and Arvinas
• JNJ-0683 (ARX788) by Johnson & Johnson

Dive Into Emerging Breast Cancer Pipelines @ https://mdatapartners.com/request-sample/pharmaceuticals/global-breast-cancer-drugs-market

Recent Developments in Breast Cancer Market

June 2025: Bristol Myers Squibb and BioNTech entered into a global strategic partnership to co-Develop and co-commercialize next-generation bispecific antibody candidate BNT327 broadly for multiple solid tumor types including triple negative breast cancer (TNBC). Under the agreement, BMS will pay BioNTech $1.5 billion in an upfront payment and $2 billion total in non-contingent anniversary payments through 2028. These tax-deductible charges will be recorded as Acquired IPR&D Expense when incurred, with the $1.5 billion being incurred in Q2. In addition, BioNTech will be eligible to receive up to $7.6 billion in additional development, regulatory and commercial milestones. BioNTech and BMS will share joint development and manufacturing costs on a 50:50 basis, subject to certain exceptions. Global profits/losses will be equally shared between BioNTech and BMS.

Immediate Delivery Available | Order This Premium Research
https://mdatapartners.com/order-report/pharmaceuticals/global-breast-cancer-drugs-market

mDataPartners LLP
Ricky Khedekar
sales@mdatapartners.com
+91 9860854331
www.mdatapartners.com

About mDataPartners LLP:
mDATA PARTNERS (MEDICAL DATA PARTNERS) is a specialized healthcare intelligence firm focused on competitive intelligence and data-driven forecasting for the pharmaceutical and medical device sectors. We empower healthcare businesses, policymakers, and industry leaders with high-quality, data-driven market research reports-both free and premium-that simplify complex healthcare trends into actionable intelligence.

This release was published on openPR.